Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Dilip Davda has given "May Apply" recommendation to Entero Healthcare Solutions IPO. Capital Market recommend to "Avoid" the IPO.SBICAP Securities Limited has "Not Rated" the IPO.
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 1 | 0 | 1 | 1 |
| % | 0.00 | 33.33 | 0.00 | 33.33 | 33.33 |
| Reviewer | Recommendation | Past Reviews |
|---|---|---|
Capital Market |
Avoid |  |
| Dilip Davda | May Apply | |
| SBICAP Securities Limited |
Not Rated | |
The Captial Market (CapitalMarket.com) rating for Entero Healthcare Solutions IPO is 38. Their analysis recommends Do not subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 38 | Do not subscribe |
[Dilip Davda] The company is one of the leading and fastest growing healthcare product distributor in India. EHSL marked losses for FY21 to FY23 and turned the corner for H1 of FY24. Based on annualized FY24 earnings, the issue appears aggressively priced, discounting all near term positives. Well-informed/risk seeker/cash surplus investors may park funds for the long term reward as it holds prospects going forward. Read detail review...
Entero Healthcare Solutions Limited peer comparison with similar listed entities. (As on March 31, 2023)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | -3.43 | -3.43 | 174.21 | -1.86 | Consolidated | ||
| Medplus Health Services Limited | 4.17 | 4.17 | 124.93 | 177.21 | 3.36 | 5.91 | Consolidated |
Notes:
(a) Financial information for Company is derived from the Restated Consolidated Financial Information for the year ended March 31, 2023
For listed peers:
(b) All the financial information for listed industry peer mentioned above is on a consolidated basis and is sourced from the annual reports/annual results as available of the respective company for the year ended March 31, 2023 submitted to stock exchanges.
(c) P/E Ratio has been computed based on the closing market price of equity shares on NSE on August 28, 2023, divided by the Diluted EPS.
(d) Return on Net Worth (RoNW) (%) = Net Profit / (Loss) after tax/ Net worth (Total Equity) at the end of the year.
(e)Net asset value per share (in ₹) represents net asset value per equity share post conversion. It is calculated as net worth as of the end of the relevant year divided by the number of equity share post conversion outstanding at the end of the respective year The Company shall undertake conversion of the outstanding CCPS into Equity Shares prior to filing of the Red Herring Prospectus. The conversion of such CCPS into Equity Shares shall depend on certain assumptions and variable factors based on the formula prescribed in the Shareholder's Agreement. The actual number of Equity Shares which may arise out of the conversion of CCPS may vary.
Entero Healthcare Solutions IPO Reviews, analysis and views by popular members. Read Entero Healthcare Solutions Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 1 | 0 | 0 | 4 |
| % | 20.00 | 0.00 | 0.00 | 80.00 |
| Member | Review |
|---|---|
| raj kk |
Avoid It's a clear avoid |
| Redfox |
Apply for Long Term at Upper Price Band Currently three organized players in industry having ~7-8% market share total which is expected to go upto ~25-30% incoming 4-5 years so expect an even higher cagr of growth going forward driven by both organic and acquisitions, Which should give operating leverage leading to enhanced profitability in a business where scale is the biggest factor. February 11, 2024 4:16:39 PM |
| JAGADISH RATNAKARAM |
Avoid Avoid
|
| Boondi consultancy |
Avoid Distribution business having very less margin and company came with insane valuation.. February 9, 2024 7:36:22 AM |
| rajaipo |
Avoid very high valuation bet decent ancer but not recommended to apply February 8, 2024 10:39:53 PM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
